The FDA just updated the approval for Inclisiran—a small-interfering RNA therapy for cholesterol—by making it a front-line therapy.
Now, with just two shots a year rather than with daily statin dosing you can lower your LDL.
Novartis United States of AmericaNovartis twice-yearly* Leqvio® (inclisiran) receives FDA approval for new indication enabling first-line usenovartis.com


